Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

2(40%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_2

20%

Ph phase_1

80%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

4(80.0%)

Phase 2Efficacy & side effects

1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(2)

Detailed Status

Completed2

Recruiting1

Not yet recruiting1

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 14 (80.0%)

Phase 21 (20.0%)

Trials by Status

recruiting120%

not_yet_recruiting120%

active_not_recruiting120%

completed240%

Recent Activity

2 active trials

Showing 5 of 5

completedphase_1

Clinical Trials (5)

Showing 5 of 5 trials

NCT07034768Phase 1

A Study to Evaluate EDG-7500 in People With Renal Impairment

Completed

NCT07324616Phase 1

A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment

Recruiting

NCT07456059Phase 1

A Study to Evaluate EDG-7500 in Caucasian and Japanese Adults

Not Yet Recruiting

NCT06347159Phase 2

A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)

Active Not Recruiting

NCT06011317Phase 1

A Study of EDG-7500 in Healthy Adults

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5